ISOPTO CETAPRED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ISOPTO CETAPRED (ISOPTO CETAPRED).
Combination of sulfonamide antibiotic (sulfacetamide) and corticosteroid (prednisolone). Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene production.
| Metabolism | Sulfacetamide: hepatic acetylation; Prednisolone: hepatic metabolism via CYP3A4 |
| Excretion | Renal: sulfacetamide is excreted unchanged in urine (30-40%); prednisolone is metabolized and excreted renally (10-20%) and fecally (30-40%) as conjugates. |
| Half-life | Sulfacetamide: 7-13 hours (prolonged in renal impairment); Prednisolone: 2.5-3.5 hours (independent of dose). Total duration of anti-inflammatory effect exceeds half-life due to genomic effects. |
| Protein binding | Sulfacetamide: ~50% bound to albumin; Prednisolone: 70-90% bound (corticosteroid-binding globulin and albumin). |
| Volume of Distribution | Sulfacetamide: 0.15-0.30 L/kg; Prednisolone: 0.4-0.7 L/kg. Both distribute well into ocular tissues. |
| Bioavailability | Ocular: sulfacetamide bioavailability is ~10-20% of applied dose (systemic); prednisolone ocular bioavailability is ~10-15% (systemic). Oral: not applicable. |
| Onset of Action | Ocular administration: sulfacetamide achieves bacteriostatic levels within 30 minutes; prednisolone anti-inflammatory effect begins within 1-2 hours. |
| Duration of Action | Ocular: sulfacetamide bacteriostatic effect persists 4-6 hours; prednisolone anti-inflammatory effect lasts 6-12 hours (dose-dependent). |
1-2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe cases, may be administered every 1-2 hours until response then gradually taper.
| Dosage form | SUSPENSION |
| Renal impairment | No dosage adjustment required due to negligible systemic absorption after topical ophthalmic administration. |
| Liver impairment | No specific hepatic adjustment required; ophthalmic use results in minimal systemic exposure. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use only if potential benefit justifies risk. No specific weight-based guidelines available. |
| Geriatric use | Elderly patients may be more susceptible to adverse effects (e.g., increased intraocular pressure); use with caution and monitor intraocular pressure regularly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ISOPTO CETAPRED (ISOPTO CETAPRED).
| Breastfeeding | Systemic corticosteroids are excreted in breast milk, but ophthalmic use results in minimal systemic absorption. M/P ratio unknown; likely negligible. Considered compatible with breastfeeding with caution. |
| Teratogenic Risk | First trimester: Corticosteroids are associated with a small increased risk of oral clefts (absolute risk ~0.1-0.3%). Second and third trimesters: No proven teratogenic risk; possible fetal growth restriction with systemic use, but ophthalmic administration results in negligible systemic absorption. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to sulfonamides or prednisolone","Epithelial herpes simplex keratitis (dendritic keratitis)","Viral diseases of the cornea and conjunctiva (e.g., vaccinia, varicella)","Mycobacterial or fungal infections of the eye"]
| Precautions | ["Prolonged use may lead to cataracts, glaucoma, or secondary infections (including fungal).","May mask signs of infection or cause exacerbation of infections.","Sulfonamide hypersensitivity reactions possible.","Monitor intraocular pressure if used for 10+ days.","Not for use in viral or fungal infections of the eye."] |
Loading safety data…
| Fetal Monitoring |
| Monitor intraocular pressure, visual acuity, and corneal integrity. In pregnancy, monitor for signs of fetal growth restriction if prolonged high-dose systemic exposure occurs (unlikely with ophthalmic use). |
| Fertility Effects | No direct evidence of impaired fertility in humans; animal studies with high doses show some reproductive effects, but ophthalmic route minimizes systemic exposure. |